Assignee
CHEMOCENTRYX INC
US·195 granted patents·79 pending applications·1,369 citations·filing 2000–2025
Top patents by PatentIndex Score
274 records- 0199US7884110B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2008·Granted Feb 8, 2011·41 cites·6 claims
- 0298US11426364B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·10 cites·6 claims
- 0398US9834545B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2016·Granted Dec 5, 2017·26 cites·33 claims
- 0498US7622583B2Heteroaryl sulfonamides and CCR2CHEMOCENTRYX INC·Filed 2006·Granted Nov 24, 2009·106 cites·5 claims
- 0597US11485708B2Compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·9 cites·21 claims
- 0697US11266643B2Triaryl compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Mar 8, 2022·13 cites·32 claims
- 0797US11135210B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Oct 5, 2021·10 cites·23 claims
- 0897US11045469B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Jun 29, 2021·5 cites·18 claims
- 0997US10639284B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2017·Granted May 5, 2020·17 cites·30 claims
- 1097US10035768B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Jul 31, 2018·23 cites·10 claims
- 1197US9809581B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2016·Granted Nov 7, 2017·23 cites·29 claims
- 1297US9745312B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2016·Granted Aug 29, 2017·13 cites·19 claims
- 1397US9573897B2C5AR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Feb 21, 2017·24 cites·9 claims
- 1496US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 1596US11691985B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2021·Granted Jul 4, 2023·4 cites·20 claims
- 1696US11478460B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·34 claims
- 1796US11059834B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·10 cites·18 claims
- 1896US11026935B2Free base crystalline form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Jun 8, 2021·5 cites·9 claims
- 1996US10919852B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2018·Granted Feb 16, 2021·15 cites·25 claims
- 2096US10568874B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Feb 25, 2020·13 cites·26 claims
- 2196US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 2296US9394307B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2013·Granted Jul 19, 2016·15 cites·19 claims
- 2396US8906938B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Dec 9, 2014·28 cites·5 claims
- 2495US11708326B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Jul 25, 2023·4 cites·25 claims
- 2595US10792360B1Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Oct 6, 2020·6 cites·16 claims
- 2695US10660897B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted May 26, 2020·6 cites·5 claims
- 2795US10583131B2Methods of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2019·Granted Mar 10, 2020·8 cites·21 claims
- 2895US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 2995US7718683B2Triazolyl phenyl benzenesulfonamidesCHEMOCENTRYX INC·Filed 2007·Granted May 18, 2010·39 cites·4 claims
- 3095US6559160B1Compounds and methods for modulating cxcr3 functionCHEMOCENTRYX INC·Filed 2000·Granted May 6, 2003·73 cites·22 claims
- 3194US11142521B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 12, 2021·4 cites·6 claims
- 3294US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 3394US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 3494US10398685B2Methods of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2019·Granted Sep 3, 2019·6 cites·20 claims
- 3594US10370363B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2017·Granted Aug 6, 2019·6 cites·13 claims
- 3694US10336736B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2017·Granted Jul 2, 2019·6 cites·24 claims
- 3794US10329314B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted Jun 25, 2019·12 cites·21 claims
- 3894US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 3994US7790726B2Monocyclic and bicyclic compounds and methods of useCHEMOCENTRYX INC·Filed 2006·Granted Sep 7, 2010·34 cites·7 claims
- 4094US7262204B2Modulation of CCR4 functionCHEMOCENTRYX INC·Filed 2003·Granted Aug 28, 2007·87 cites·18 claims
- 4193US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 4293US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 4393US10828285B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Nov 10, 2020·5 cites·27 claims
- 4493US10392405B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2018·Granted Aug 27, 2019·13 cites·46 claims
- 4593US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 4693US10251888B2Method of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2017·Granted Apr 9, 2019·9 cites·8 claims
- 4793US7807704B2Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2CHEMOCENTRYX INC·Filed 2007·Granted Oct 5, 2010·30 cites·18 claims
- 4893US7582661B2Aryl sulfonamidesCHEMOCENTRYX INC·Filed 2005·Granted Sep 1, 2009·18 cites·17 claims
- 4992US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 5092US11382915B2Treatment of focal segmental glomerulosclerosis with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Jul 12, 2022·2 cites·20 claims
Showing the top 50 of 274 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CHEMOCENTRYX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →